Comparative Pharmacology
Head-to-head clinical analysis: IBUPRIN versus NALFON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPRIN versus NALFON.
IBUPRIN vs NALFON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
Fenoprofen, a propionic acid derivative, nonselectively inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
200-800 mg orally every 6-8 hours as needed; maximum daily dose 3200 mg.
NALFON (fenoprofen) 200-600 mg orally 3-4 times daily; maximum dose 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours; in elderly or patients with hepatic impairment, half-life may be prolonged to 6-8 hours.
3-4 hours (terminal half-life in healthy adults; prolonged in elderly and hepatic impairment).
Renal excretion of conjugated metabolites (75-85%), with less than 10% excreted unchanged; biliary/fecal elimination accounts for less than 10%.
Renal: 90% (mostly as glucuronide conjugates and unchanged drug; unchanged drug ~1-5%); Fecal: <5%; Biliary: negligible.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)